HOME >> MEDICINE >> NEWS
Lexapro receives FDA approval for the treatment of generalized anxiety disorder

NEW YORK, December 18 - Forest Laboratories, Inc. (NYSE:FRX) announced today that the U.S. Food and Drug Administration (FDA) has approved Lexapro (escitalopram oxalate), a selective serotonin reuptake inhibitor (SSRI), for the treatment of generalized anxiety disorder (GAD), a condition that affects approximately four million Americans annually. The new indication is based on three studies, all of which were positive and support the efficacy and safety of Lexapro in the treatment of GAD. GAD is characterized by excessive anxiety and worry that significantly impacts an individual's daily functioning. Lexapro is also indicated for the initial treatment and maintenance of major depressive disorder.

"One of the biggest challenges in treating GAD patients is finding a treatment that is not only effective, but also one that patients will be able to tolerate for the long term," said Philip Ninan, M.D., professor of Psychiatry and Behavioral Sciences and director of the Mood and Anxiety Disorders Program at Emory University School of Medicine. "Lexapro is a first-line treatment option, which has proven to be effective with a favorable side effect profile."

Study Details

All three studies that support the indication approval were randomized, double-blind, eight weeks in duration and placebo-controlled. The studies involved approximately 850 patients, 18 to 80 years of age, diagnosed with GAD. Patients in the Lexapro arm were administered a fixed dose of 10 mg per day for the first four weeks and then flexibly dosed to a maximum of 20 mg per day. The Hamilton Anxiety Scale (HAMA) total score was the primary efficacy variable, and secondary efficacy measures included changes in HAMA psychic anxiety subscale and Clinical Global Impressions (CGI) scores. In each of the three studies, Lexapro 10 to 20 mg per day significantly improved GAD symptoms in patients compared to placebo as measured by change from baseline in HAMA score. By-visit anal
'"/>

Contact: Charles E. Triano
212-224-6714
Forest Laboratories
18-Dec-2003


Page: 1 2

Related medicine news :

1. Starting dose of Lexapro as effective as optimally dosed Zoloft in the treatment of depression
2. UIC professor receives international humanitarian award
3. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
4. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award
5. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
6. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
7. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program
8. American Academy of Neurology program receives Grassroots Award
9. Orqis receives FDA approval to expand clinical trial of Cancion CRS therapy to 40 centers
10. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI
11. Pfizers antifungal medicine VFEND receives FDA approval

Post Your Comments:
(Date:3/2/2015)... 2015 Gummy smile reduction expert, ... reshaping can involve one or several procedures to reduce the ... tissue for a more even gum line. Dr. Farnoosh is ... that can permanently lighten discolored or naturally dark gums. ... involves a personalized treatment plan to address a patient’s specific ...
(Date:3/2/2015)... SAN ANTONIO (PRWEB) March 02, 2015 ... as quality processes, customer service, pricing and long-term strategy, ... as its vendor of choice for member centers’ testing ... blood centers and represents more than 30 percent of ... recent member meeting. , “BCA is committed to drive ...
(Date:3/2/2015)... York, New York (PRWEB) March 02, 2015 ... Creative Recovery at Recovery Unplugged™—will be delivering a ... A Singer/Songwriter's Perspective on the Art of Healing ... Addiction Disorders (NCAD) and Behavioral Healthcare Executive Summit ... his name, Mr. Supa’s songs have been recorded ...
(Date:3/2/2015)... 2015 Over the last five years ... vendors seeking to expand their geographic presence and achieve ... to reach $6.2 billion by 2019 at CAGR of ... the U.S. and Canada and a major part of ... regions such as Asia-Pacific including China and India, Latin ...
(Date:3/2/2015)... The minimally invasive surgical instruments market ... 6.1% to reach $14,133.0 million by 2019 from ... as advantages of minimally invasive surgeries over traditional ... invasive surgeries and increasing number of surgical procedures ... minimally invasive surgical instruments market. , For More ...
Breaking Medicine News(10 mins):Health News:Gummy Smile Expert, Dr. Alex Farnoosh, is Now Offering Gum Reshaping Procedures 2Health News:Blood Centers of America Chooses QualTex Laboratories as Vendor of Choice 2Health News:Blood Centers of America Chooses QualTex Laboratories as Vendor of Choice 3Health News:Richie Supa Announced as a Plenary Speaker at NCAD 2015 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2
(Date:3/2/2015)... , March 2, 2015   Polymedco is committed to ...  During CRC Awareness Month, we are offering all existing ... , Posters – to be hung in ... CRC Patient Brochures with Stand – to be placed ... – to be put on/in patient charts as a ...
(Date:3/2/2015)... 2015  Kush Bottles, North America,s ... for the marijuana industry, announced today that its CEO ... nominated for a 2015 Excellence in Entrepreneurship Award.  ... is designed to recognize individuals who exemplify the ... creativity and determination, have established and nurtured successful ...
(Date:3/2/2015)... NEW YORK , March 2, 2015 /PRNewswire/ ... LLC is investigating potential claims on behalf of ... ("Vitae Pharmaceuticals" or the "Company") (NasdaqGM: VTAE -News).  ... Bronstein or his investor relations coordinator ... 212-697-6484. The investigation concerns whether Vitae ...
Breaking Medicine Technology:Polymedco CDP, LLC. Promotes March as Colorectal Cancer Awareness Month 2Kush Bottles CEO, Nicholas Kovacevich, Nominated for 2015 "Excellence in Entrepreneurship Award" 2SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Vitae Pharmaceuticals, Inc. 2
Cached News: